Trials / Completed
CompletedNCT00927810
Long Term Study of Canakinumab (ACZ885) in Patients With Gout
A 24-week Open-label, Multicenter, Follow-up and Extension Study to CACZ885H2251, to Assess Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients With Gout Who Were Given Canakinumab at the Time of Gout Flare
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 341 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This 24-week open-label extension study is designed to provide additional long-term safety data up to a total of 1-year for patients rolling over from the core study, and to collect further efficacy and tolerability data for all the patients, irrespective whether they have an acute flare of gout or not. Patients will be treated on demand with canakinumab (ACZ885) in this extension study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Canakinumab |
Timeline
- Start date
- 2009-06-05
- Primary completion
- 2010-08-04
- Completion
- 2010-08-04
- First posted
- 2009-06-25
- Last updated
- 2021-07-02
- Results posted
- 2021-06-09
Locations
45 sites across 18 countries: United States, Argentina, Belgium, Colombia, Czechia, Germany, Guatemala, Hungary, Poland, Portugal, Russia, Singapore, Slovakia, South Africa, Spain, Taiwan, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT00927810. Inclusion in this directory is not an endorsement.